BRAIN Biotech AG
XETRA:BNN
P/FCFE
Price to FCFE
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | P/FCFE | ||||
---|---|---|---|---|---|
DE |
BRAIN Biotech AG
XETRA:BNN
|
61.2m EUR | -12.7 | ||
JP |
Shin-Etsu Chemical Co Ltd
TSE:4063
|
12.1T JPY | 28.2 | ||
US |
Sherwin-Williams Co
NYSE:SHW
|
77.1B USD | 49 | ||
US |
Ecolab Inc
NYSE:ECL
|
64.3B USD | 74 | ||
CH |
Sika AG
SIX:SIKA
|
42.2B CHF | 15.4 | ||
CH |
Givaudan SA
SIX:GIVN
|
36.6B CHF | 42 | ||
CN |
Wanhua Chemical Group Co Ltd
SSE:600309
|
279.8B CNY | 15.9 | ||
US |
Dupont De Nemours Inc
NYSE:DD
|
33.7B USD | 59.3 | ||
IN |
Asian Paints Ltd
NSE:ASIANPAINT
|
2.9T INR | 75.6 | ||
US |
PPG Industries Inc
NYSE:PPG
|
30.7B USD | 71.9 | ||
CH |
D
|
DSM-Firmenich AG
AEX:DSFIR
|
28.1B EUR | -304.2 |
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.